Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208678 | 0.83 | CA12 (0.57) | CYP3A4MAPK1USP2SMN1; SMN2LMNA | |
| SCHEMBL5274484 | 0.81 | MAP2K1 (0.48) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL4743848 | 0.80 | CYP3A4 (0.66) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL2029772 | 0.80 | CYP3A4 (0.78) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL12248741 | 0.80 | CYP3A4 (0.60) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL23327143 | 0.78 | MAPK1 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL23327273 | 0.78 | CYP3A4 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL116728 | 0.78 | CYP3A4 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL23327352 | 0.78 | CYP3A4 (0.53) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A | |
| SCHEMBL24488712 | 0.78 | TSHR (0.52) | CYP3A4MAPK1USP2SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403251-B1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6890940-B2 | Bis(2-aryl-5-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1403251-A1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | CYP3A4 2455/4885MAPK1 403/4885USP2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.